Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Wound Management Technologies — Investor Presentation (January 2011)
22 slides from Sanara Medtech's investor presentation, Jan 7, 2011
Slide 1: Wound Management Technologies, Inc.
Wound Mana gement TECHNOLOGIES, INC. “The clinical results we have observed have validated the science behind the product. |would highly recommend CellerateRX® to any conscientious wound care provider.“ Desmond P. Bell, Jr. DPM President and Co-Founder "Save A Leg, Save A Life" Foundation
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this Presentation are made as of the date of this Presentation unless stated otherwise and are subject to change, completion, or amendment without notice. Neither the delivery of this Presentation at any time shall under any circumstances create an implication tha
Slide 3: Investor Highlights
> Investor Highlights Emerging commercial stage company positioned to move to cash flow positive & profitability in coming 12-24 months Rapid revenue growth projected led by FDA cleared CellerateRX® wound care products - Advanced wound care products market is $5B worldwide and growing Recent market
Slide 4: Wound Management Technologies subsidiaries
Wound Management QI) TECHNOLOGIES, INC. BIOTECH eHEALTH Secure Health... vd yJ> RESORBABLE OP ORTHOPEDIC PRODUCTS, LLG Copyright © 2011 Wound Management Technologies Inc. 4
Slide 5: Wound Care Innovations: CellerateRX advantage
Wound Care Innovations, LLC §M@S2ge/]0en The CellerateRX® advantage is in the patented, Activated Collagen™ fragments (CRXa™) combined with the properties of the Type |, bovine-sourced, material. CellerateRX ® provides the wound site with a form of collagen that is unique as it is ready to be used i
Slide 6: Why CellerateRX?
Why CellerateRX? > CellerateRX® is available in powder and gel forms > It is a unique, patented, activated collagen that delivers immediate benefits to the wound > Cost-effective > Both in product cost and in the cost of labor involved > Biocompatible and biodegradable > Unprecedented range of use i
Slide 7: CellerateRX Regulatory Status
wnom &) CellerateRX® Regulatory Status v Reimbursed by Medicare Part B v Regulated as a medical device > CellerateRX® does not require a prescription } > FDA cleared for all wounds* including: 1 i E f I J Except 3” degree burns ¥ Certifications in process: > ISO 9001:2008/13485:2003/CMDCAS and MDD(C
Slide 8: Chronology of Wound Healing
9995 eS) 99005 \-] Chronology of Wound Healing CellerateRX’s activated collagen fragments Chronology of Wound Healing (CRX,,) deliver the essential benefits of inky collagen to the wound immediately ‘Macro environment Collagen is essential to wound healing CellerateRX® can be used in all phases of w
Slide 9: Numerous Evidence Based Studies by Leading Clinicians
Numerous Evidence Based Studies by Leading Clinicians vat The 6th Annual High Risk Diabetic Foot Conference + Dr. Gary Rothenberg, DPM, CDE, cws_* Gregory B. Pott PhD, K. Scott Beard MS, (Miami VA) Matthew Regulski, DPM and Leland * Dr. Jane Fore, MD, FAPWCA, Shapiro MD Department of Medicine, FACCW
Slide 10: Efficacy of CellerateRX, Real World Examples
Efficacy of CellerateRX®, Real Wort Examples “Activated Collagen: An evidence Based Study in Human Leg Ulcers”, Dr. Matthew Regulski, Director, Wound Care Center of Ocean County, NJ Results: All powder treated wounds were healed by 5 weeks. Control wounds were approximately 80% healed at 12 weeks. “
Slide 11: Efficacy of CellerateRX Examples, Continued
, Real Wort Efficacy of CellerateRX® Examples, Continued “Activated Collagen Accelerates Wound Repair and Modulates Cytokine Production in Whole Blood and PBMC Cultures’ Dr. Gregory Pott, Dr. K. Scott Beard, Dr. Matthew Regulski, Dr. Leland Shapiro, Department of Medicine, Denver Veterans Medical Ce
Slide 12: Sales Team in Place
Sales Team in Place > Poised for Growth: having completed evidence- based studies , Wound Management developed its sales channel plan and engaged sales and marketing executives in April 2010. > Growth from: — Growing brand recognition — New direct reps in Florida and Texas — Management of independen
Slide 13: Major Deals & Opportunities Forecast
Major Deals & Opportunities Forecast over 50 relationships in process (2011) * TV/Retail Distributors: @$2.5M+ in 2011 — Kick off mid-January 2011 * Government Initiatives: @$1M+ in 2011 — Announcements 3 Q; GMP meeting 12/14 — EWA — 10 VHA hospitals now use CellerateRX + Major Wholesalers: @250k+ i
Slide 14: Mithra Research: Taming the Divine Bull
ut MITHRA RESEARCH j “Taming the Divine Bull” Independent Research published July 28, 2010 We are of the opinion that CellerateRX® ought to be standard issue in every hospital, emergency rooms, every soldier's field kit; it should be in the medical supplies of schools and Universities; every student
Slide 15: Biotech Pipeline
Biotech Pipeline QOP RESOR BABLE ORTHOPEDIC PRODUCTS, LLC Resorbable Bone Wax & Bone Void Filler products > $1.4B Worldwide Bio Materials Market » Resorbable orthopedic hemostat used to stop blood flow & delivery system for osteogenic / osteoinductive orthopedic products > Less than $100k to finaliz
Slide 16: Secure eHealth
Secure eHealth.. >» Secure eHealth technology to be featured as part of the Interoperability Showcase at ... February 20% — 24 - Orlando, FL » Will demonstrate the systems ability to securely transport clinical documentation as part of a fully integrated solution with multiple partners > \nconjuncti
Slide 17: Stock Overview
Stock Overview Wound Management Technology, Inc. (WNDM) is a rapidly growing provider of advanced biotechnology products and eHealth technology solutions. = Symbol: WNDM = Exchange: OTC = Shares Outstanding: 37,661,225 (3Q 2010) = Estimated Float: 3.3M = Last Trade: $0.40 (1/04/2011) = Market capita
Slide 18: Financial Highlights & Projections
7,000,000 6,000,000 5,000,000 4,000,000 3,000,000 2,000,000 1,000,000 0 -2,000,000 -3,000,000 -1,000,000 - Financial Highlights & Projections 2009 2010e e==Revenue ____ #@Net Income 2011e Revenue 288,021 Net Income) (2,302,527) EO) (2,200,000)" 6,000,000 1,400,000 "Without nor operatonal css Copyrig
Slide 19: Value Growth Milestones
18 Month Value Growth Milestones > Targeted to be cash flow positive & profitable > US Market rollout of CellerateRX® in retail, healthcare, and US government system markets — Direct to consumer sales to the retail channels (TV and Internet) will be substantial and will help promote product awarenes
Slide 20: Wound Management Technologies contact
WY, | Wound Management SD } TECHNOLOGIES, INC. 777 Main Street, Suite 3100 Fort Worth, Texas 76102 USA +1 (817) 820-7080 www.wmgtech.com www.CellerateRX.com Deborah Jenkins Hutchinson djenkins@wmgtech.com Copyright © 2011 Wound Management Technologies Inc. 20
Slide 21: Management
Management > Scott Haire, Chairman/CEO/CFO, has extensive management experience including experience in the healthcare and technology sectors. Prior to Wound Management, he was President of Preferred Payment Systems and CEO of Medbanc Data Corporation. > Deborah Jenkins Hutchinson, President, Direct
Slide 22: Management, continued
Management, continued >» Cathy Bradshaw, President, Wound Care Innovations, LLC Division. Cathy has over 25 years of healthcare management experience in homecare, pharmacy & infusion services, long term care, and DME, including serving as SE Regional VP at Ivonyx, Inc. (home infusion) and Sr. VP of
Wound Management Technologies — Investor Presentation (January 2011) on 6ix